AGS-16M18

N/A

Report date: 2022/07/04 19:38:02

Base Information

Drug NameAGS-16M18

Drug Alias Nameanti-AGS-16 MAbanti-AGS-16 antibody therapyAGS-16M18

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human

Mechanisms of ActionSurface antigens inhibitors

TargetsSurface antigens

Therapy Area/IndicationsKidney DiseasesKidney NeoplasmsCarcinoma, Renal Cell

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusDiscontinued (Phase 1 Clinical)

Highest Status in ChinaN/A

Originator CompaniesAstellas Pharma Inc

China Registration ClassN/A

Active CompaniesN/A

Active IndicationsN/A

Inactive IndicationsKidney DiseasesKidney NeoplasmsCarcinoma, Renal Cell

ATC CodeN/A